Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2024

	June 30,		December 31,
	2024		2023
Prepaid expenses and other current assets:
Prepaid insurance	$	83,627	$	426,413
Prepaid research and development costs		27,534		91,232
Prepaid other and other current assets		61,536		22,854
Deferred offering costs		116,755		-
Total prepaid expenses and other current assets	$	289,452	$	540,499

Accrued and other current liabilities:
Accrued research and development costs	$	263,018	$	40,596
Accrued compensation and benefits		277,963		716,490
Accrued other		50,265		502
Total accrued and other current liabilities	$	591,246	$	757,588